Long-acting progestin-only contraceptives impair endometrial vasculature by inhibiting uterine vascular smooth muscle cell survival.
Umit A Kayisli, Murat Basar, Ozlem Guzeloglu-Kayisli, Nihan Semerci, Helen C Atkinson, John Shapiro, Taryn Summerfield, S Joseph Huang, Katja Prelle, Frederick Schatz, Charles J Lockwood
文献索引:Proc. Natl. Acad. Sci. U. S. A. 112(16) , 5153-8, (2015)
全文:HTML全文
摘要
Molecular mechanisms responsible for abnormal endometrial vasculature in women receiving long-acting progestin-only contraceptives (LAPCs) are unknown. We hypothesize that LAPCs impair vascular smooth muscle cell (VSMC) and pericyte proliferation and migration producing thin-walled hyperdilated fragile microvessels prone to bleeding. Proliferating cell nuclear antigen (PCNA) and α-smooth muscle actin (αSMA) double-immunostaining assessed VSMC differentiation and proliferation in endometria from women before and after DepoProvera (Depo) treatment and from oophorectomized guinea pigs (OVX-GPs) treated with vehicle, estradiol (E2), medroxyprogesterone acetate (MPA), or E2+MPA. Whole-genome profiling, proliferation, and migration assays were performed on cultured VSMCs treated with MPA or etonogestrel (ETO). Endometrial vessels of Depo-administered women displayed reduced αSMA immunoreactivity and fewer PCNA (+) nuclei among αSMA (+) cells (P < 0.008). Microarray analysis of VSMCs identified several MPA- and ETO-altered transcripts regulated by STAT1 signaling (P < 2.22 × 10(-6)), including chemokine (C-C motif) ligand 2 (CCL2). Both MPA and ETO reduce VSMC proliferation and migration (P < 0.001). Recombinant CCL2 reversed this progestin-mediated inhibition, whereas a STAT1 inhibitor abolished the CCL2 effect. Similarly, the endometria of MPA treated OVX-GPs displayed decreased αSMA staining and fewer PCNA (+) nuclei in VSMC (P < 0.005). In conclusion, LAPCs promote abnormal endometrial vessel formation by inhibiting VSMC proliferation and migration.
相关化合物
相关文献:
2014-01-01
[Retrovirology 11 , 118, (2015)]
2014-01-01
[PLoS ONE 9(9) , e108055, (2014)]
2014-07-07
[Mol. Pharm. 11(7) , 1991-6, (2014)]
2015-02-01
[Cancer Chemother. Pharmacol. 75(2) , 431-7, (2015)]
2015-02-15
[Food Chem. 169 , 28-33, (2014)]